SecBot SecBot

BCAX

Bicara Therapeutics Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0002023658 Biotech & Drug Discovery
$10.02 −0.09 (−0.89%)
Nov 13 4:00 PM ET · prev $10.11
Market cap
$671.2M
Small cap
Consensus
Buy
90% Buy or better · 20 analysts
Median target
$34.50
+244% · range $8.00–43.00
1 year
−33.4%
from $15.05 · Nov 17
30 days
−42.6%
from $17.47
52-week range
$7.93–30.40
−67% from high · low Nov 2
Avg volume 20D
2.24M
Oct 28 spike 15.43M
Short interest
9.86M
≈14.9% of shares · −4.2%
Days to cover
3.8
at average volume
Insider net
−$4.9M
0 buyers · 4 sellers · since Apr 16
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
20
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 4/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $4.9M.

  • InstitutionsBULLISH

    Q3 2026: 22 added (0 new), 7 trimmed or exited.

  • AnalystsBULLISH

    18 of 20 rate it Buy or better. Median target $34.50 (+244%).

  • EstimatesFLAT

    Current-quarter EPS estimate −$0.848 → −$0.861 over 90 days. 7 up, 3 down in 30 days.

  • Short sellersSTEADY

    Short interest −4.2% to 9.86M shares. 3.8 days to cover, ≈14.9% of shares.

  • TrendDOWNTREND

    40% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
FRANKLIN TEMPLETON INCADD2,665,137$23.7M
JPMORGAN CHASE & COTRIM716,481$13.3M
DIMENSIONAL FUND ADVISORS LPADD656,915$12.2M
Jump Financial, LLCDOUBLED228,516$4.3M
CITIGROUP INCDOUBLED192,569$3.6M
TD ASSET MANAGEMENT INCTRIM175,692$3.3M
Hudson Bay Capital Management LPADD165,000$3.1M
UBS Group AGDOUBLED133,932$2.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 90% rate it Buy or better
Strong Buy7Buy11Hold1Sell1Strong Sell0
12-month targets · 12 analysts

Price is inside the target range. Median implies +244%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Nov 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Nov 10, 2026Morgan Stanley
MAINTAIN
MAINTAINOverweight
Nov 10, 2026Stifel
MAINTAIN
MAINTAINBuy
Nov 10, 2026BTIG
MAINTAIN
MAINTAINBuy
Oct 30, 2026Goldman Sachs
DOWNGRADE
DOWNGRADESell
Oct 29, 2026Wedbush
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$4.9M
sold · 4 insiders
DateInsiderTypeValue
Sep 8, 2026
Cohlhepp Ryan
President, COO & Interim CEO
Sep 8, 2026
EXERCISE$66.3K
Sep 8, 2026
Cohlhepp Ryan
President, COO & Interim CEO
Sep 8, 2026
SELL$80.7K
Sep 8, 2026
Cohlhepp Ryan
President, COO & Interim CEO
Sep 8, 2026
SELL$320.1K
Aug 12, 2026
Larson Jennifer
Chief Financial Officer
Aug 12, 2026
AWARD285,000 sh
Aug 10, 2026
Mazumdar Claire
Chief Executive Officer
Aug 10, 2026
EXERCISE$37.9K
Aug 10, 2026
Mazumdar Claire
Chief Executive Officer
Aug 10, 2026
SELL$279.8K
Aug 10, 2026
Cohlhepp Ryan
President and COO
Aug 10, 2026
EXERCISE$71.1K
Aug 10, 2026
Hyep Ivan
Chief Financial Officer
Aug 10, 2026
EXERCISE$47.4K

Earnings setup

Estimates
−$0.86
EPS estimate, this quarter
−1%
estimate change, 90 days
7↑ 3↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.86-$0.97–-$0.47-4.8%$0.00
Next Q-$1.01-$1.19–-$0.61-17.7%$0.00
Current FY-$3.63-$3.89–-$2.65-7.2%$0.00
Next FY-$3.89-$5.33–-$1.86-10.6%$0.00

Short side

FINRA· Oct 30, 2026
9,861,807
shares short
-4.2%
vs prior settlement
3.8
days to cover
≈14.9%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent

SecBot reports

20 filings · 6 press releases · 1 bullish · 2 bearish · 2 mixed · 15 neutral
All BCAX filing & press-release reports (26)